Archives

The original aim of the Metropolit cohort was to follow men from early school age to early mid-life, to explore intergenerational mobility and differential life-chances. In 2001 the cohort was revitalised in order to study the development of chronic diseases in a life course perspective.
The Metropolit cohort comprises all 11532 men born in 1953 in the Copenhagen Metropolitan area who were living in Denmark in 1968. These men have been followed repeatedly since their birth. In brief, we have data from birth certificates (1953) which include information on birth dimensions and father’s occupation. In 1965, 7,987 participated in a school-based survey and completed tests of cognition and enquiries regarding leisure-time activities and social aspirations. Data from draft board examinations at around age 19 have been collected for 11,108 of the men. These data include cognitive testing and health information. In 2004, 6,292 of the men responded to a mailed questionnaire with questions on health and lifestyle. In 2009-2010, 2486 of 7799 eligible cohort members participated in the Copenhagen Ageing Midlife Biobank (CAMB) study which comprised questionnaires, cognitive and physical testing as well as blood sampling. Further, around 300 men selected on their young adult and current cognitive performance have been through a neurophysiological examination including EEG, MRI, fMRI and sleep tests. The cohort has also been followed in nation-wide social and health registers for social life, medical and mental hospital diagnosis as well as cause of death from 1969 to 2016.

Last Update 21/09/2017

The aim of the Alfa Study is to focus on the processes taking place before the initiation of Alzheimer’s symptoms in order to design interventions to prevent or delay the onset of dementia. Inclusion criteria were being cognitively normal Spanish and/or Catalan-speaking persons aged between 45 and 74 years that agreed with the study procedures and tests: clinical interview and questionnaires associated to risk factors, cognitive tests, a blood sample extraction for DNA analysis, and MRI.

A subset (n=450) of the ALFA parent cohort participants are currently being recruited / undergoing a nested longitudinal long-term study, named the ALFA+ study, in which a more detailed phenotyping will be performed. On top of a similar characterization as in the ALFA parent cohort, it will entail the acquisition of both wet (CSF, blood, and urine sample collection) and imaging (magnetic resonance imaging [MRI] and PET) biomarkers. Furthermore, ALFA parent cohort participants may also be invited to participate in other BBRC studies such the ALFAlife primary intervention study (n=400) or the full genetic and neuroimaging characterisation study referred to as ALFAgenetics (n=2000).

Last Update 21/09/2017

The Rhineland Study is a prospective cohort study, which began in March 2016. It will include up to 30,000 participants from Bonn and asses their physical and mental health over their lifespan. The study is scheduled to run for decades and participants will be re-examined every 3-4 years.

As neurodegenerative diseases and their pathologies develop over a long time before first symptoms start to show, the Rhineland Study will include men and women aged 30 years and above regardless of their health status.
The main aims of the study are:

1. To investigate modifiable and non-modifiable causes of neurodegenerative and neuropsychiatric diseases
2. To find biomarkers/(multimodal) biomarker profiles to identify individuals at risk for neurodegenerative or neuropsychiatric disease, who might benefit from preventive interventions
3. To investigate (patho)physiology over the adult life course, with specific emphasis on brain-related outcomes.

Last Update 21/09/2017

The rpAD study is a longitudinal study, which recruits patients from the entire federal territory. In addition, patients from the Clinical Dementia Centre are recruited at the Neurological and Psychiatric Clinic of the University Medical Center of G’ttingen, with these usually classical clinical forms being internal controls. The aim of the study is to characterize the biological factors and parameters that define the disease progression in AD.

After the patient is informed and consent is given, the inclusion examination is carried out. It includes a detailed history and anamnesis as well as a physical examination, which includes an in-depth examination of the neurological status. A neuropsychological test for cognitive testing is performed using the CERAD-plus test battery. Furthermore, the GDS score is obtained, which allows an assessment of the severity of the cognitive deficits by means of a 7-stage classification. The ADL score is used to assess the activities of daily life (Lawton and Brody 1969).

Six months after the initial examination, a telephone follow-up is carried out. Further investigations are carried out on an annual basis and correspond to the initial examination.

Last Update 21/09/2017

The Older Australian Twins Study is a longitudinal, multi-centre study that investigates healthy brain ageing in older twins (65+ years). OATS commenced in New South Wales in January 2007, in Queensland in December 2007, and in Victoria in February 2008. Since the OATS study started we have followed our twin volunteers up every two years to check on their psychological and physical health. Participants undergo rigorous medical and cognitive function tests, with many participants’ also providing bloods samples and having a magnetic resonance imaging (MRI) scan of their brain. In 2015 we finished our 4-year follow ups. OATS assessed 623 participants at baseline, 450 at the 2-year follow up, and 389 completed their 4-year follow-up.

Last Update 21/09/2017

The key goal of EUROSCA-NHS is to determine and compare the rate of disease progression in SCA1, SCA2, SCA3 and SCA6. To this end, a newly developed and validated ataxia scale (Scale for the Assessment and Rating of Ataxia, SARA) will be used. EUROSCA-NHS has a number of secondary aims including determination of the order and occurrence of non-ataxia symptoms, assessment of activities of daily living (ADL) and quality of life (QoL), and identification of predictors of disease progression and survival.

Patients are first seen at a baseline visit, followed by annual visits for 3 years scheduled ᄆ 3 months around the specified time point. After the initial 3 year observation period, visits are done at irregular intervals each time they went to hospital.

Last update – 12/08/2017

The Norwegian ParkWest study is a prospective population-based longitudinal cohort study of patients with incident Parkinson’s Disease in Western and Southern Norway, with a total base population of more than 1 million inhabitants. The initial cohort comprised of 212 newly-diagnosed and drug-naïve individuals with suspected Parkinson’s disease, who were followed with standardized clinical examinations every 6 months. More comprehensive assessments, including neuropsychological and behavioural evaluations, were conducted at baseline and 1-year of follow-up, and at 2-year intervals thereafter. Currently, study participants are in the 10th year of follow-up. About 110 patients are still in the study.

Last update – 10/04/2017

The Southall And Brent Revisited Study (SABRE) is the largest tri-ethnic population-based cohort in the UK, involving nearly 5000 European, Indian Asian and African Caribbean men and women. It investigates the causes of diabetes and disorders of the heart and circulation and examines underlying reasons for ethnic differences in risk of these disorders.

The participants were aged 40-69 when first studied between 1989 and 1991. In 2008-2011 a comprehensive combined morbidity and mortality follow up was carried out, together with non-invasive clinical measurements in order to quantify sub-clinical disease. SABRE visit 2 tested hypotheses generated from the Southall and Brent baseline studies and ongoing mortality follow-up.

SABRE Visit 3 (25 year follow-up visit) started in July 2014 and is collecting data on index participants and new participants, including partners of index participants. The focus of this visit is on cardiac, cognitive and physical function in older age, in association with mid-life risk factors. Ethnic and gender differences in function will also be examined.

Last update – 10/04/2017

TRACK-HD was a prospective observational biomarker study in participants with premanifest and early Huntington’s disease (HD). Track-HD assessed longitudinal data collected at baseline, 12 months, 24 and 36 months at sites in Leiden (Netherlands), London (UK), Paris (France), and Vancouver (Canada). Participants were individuals without HD but carrying the mutant HTT gene (ie, premanifest HD), patients with early HD, and healthy control individuals matched by age and sex to the combined HD groups. Data were collected with 3T MRI, clinical, cognitive, quantitative motor, oculomotor, and neuropsychiatric assessments. TrackOn-HD followed on from TRACK-HD aiming to investigate compensatory mechanisms in premanifest gene carriers. Baseline, 12 and 24 month data was collected from the same four sites on premanifest gene carriers and healthy controls including 3T MRI, task and resting state fMRI, DTI, clinical, cognitive, quantitative motor and neuropsychiatric assessments.

Last update – 11/04/2017

The Northern Finland Birth Cohort Studies is an epidemiological and longitudinal research program which aims to promote health and well-being of the population. The prospective data collected from the Northern Finland forms a unique resource, allowing to study the emergence of diseases which can be based on genetic, biological, social or behavioural risk factors.

NFBC includes two longitudinal and prospective birth cohorts of women and offspring collected at 20-year intervals from the same provinces of Oulu and Lapland: The NFBC1966 was set with an expected date of birth in 1966, comprising of 12,068 mothers and 12,231 children (prospective data collection from maternity cards since 16th gestational week on average), and the NFBC1986 with an expected date of birth between July, 1st 1985 and June, 30th 1986, comprising 9,362 mothers and 9,479 children (prospective data collection from 10th gestational week).

Last update – 02/05/2017